BioMarin Pharmaceutical enters the back half of August with shorts in clear retreat and analysts lifting targets, yet the stock itself has given back ground this week — a divergence worth watching closely.
The most striking move in positioning is the sharp unwind in short interest. Shorts held roughly 14.3 million shares as recently as August 10. By August 18, that figure had fallen to 12.5 million — a 12.6% drop in a single week. At 6.5% of the free float, the short position remains meaningful for a large-cap biotech, but the direction of travel has turned decisively. The catalyst is clear: BioMarin reported Q2 results on August 6 and the stock jumped 6.5% the next day, extending to a 14.4% gain over the following five sessions. That kind of move forces short-sellers to reassess, and the data shows many did exactly that. The borrow market reflects this new equilibrium — cost to borrow has drifted between 0.28% and 0.64% over the past month, firmly in low-cost territory, and share availability is extraordinarily loose at over 6,000% of short interest. There is no squeeze pressure here, and no sign the remaining shorts face any constraint in holding their positions.
Options positioning tells a similarly relaxed story. The put/call ratio at 0.35 is barely above its 20-day average of 0.35, generating a z-score close to zero. Options traders are neither hedging aggressively nor piling into calls — sentiment in the derivatives market is simply neutral. The 52-week PCR range runs from 0.28 to 0.69, and the current reading sits near the lower end, suggesting the prevailing lean remains slightly bullish but without conviction either way.
The Street has turned notably more constructive following the earnings beat. Barclays raised its target to $111 from $105 on August 17, maintaining Overweight. Piper Sandler moved from $82 to $88 the same day. Morgan Stanley was even more emphatic on August 7, lifting its target to $124 from $119 while keeping Overweight. BMO Capital initiated coverage this week at Outperform with a $98 target. Those bullish targets sit well above the consensus mean of $91 — and far above the stock's current price of $66.99 — implying roughly 36% upside on the consensus view. The one dissenting note comes from HC Wainwright, which trimmed its target to $59, the only figure below the current price and a useful reminder that not everyone is convinced. The forward earnings picture supports the bull case: the forward EPS year-on-year growth factor scores in the 96th percentile of the universe, and the analyst recommendation differential ranks in the 93rd. On valuation, the stock trades at a trailing P/E of 11.2 and EV/EBITDA of 9.6 — modest multiples for a rare-disease specialist with a growing commercial portfolio. The bear case centers on competitive pressure from Ascendis Pharma's YUVIWEL, which offers once-weekly dosing against VOXZOGO's daily injection, and from Amicus' advancing gene therapies. Switching rates and market share erosion in achondroplasia remain the key variables bears are watching.
Peers have generally fared better this week. VRTX was roughly flat on the week and AMGN gained 2.7%, while INSM fell 3.1% — making BMRN's 3.7% weekly decline look more like stock-specific digestion than sector weakness. The ORTEX short score has also eased, dropping from around 49.8 on August 5 to 46.0 now, consistent with the short unwind and a less hostile positioning environment overall.
The next scheduled catalyst is Q3 earnings on October 27. Between now and then, the key variable is how quickly VOXZOGO's U.S. growth holds up against YUVIWEL's commercial launch — any prescription data or competitor commentary at upcoming medical conferences will be the metric that determines whether the remaining 6.5% short position continues to shrink or finds reason to rebuild.
See the live data behind this article on ORTEX.
Open BMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
